Mohammad Alizadeh

Elevated Brain-Derived Neurotrophic Factor Correlates Negatively with Severity and Duration of Major Depressive Episodes.

Background and Objective:Major depressive disorder is a neuropsychiatric condition associated with neurochemical changes that alter levels of neurotrophins. We aimed to measure serum levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF) in patients experiencing their first episode of major depression and to examine those levels in relation to the severity and duration of the depressive episode. Methods:We recruited 85 participants: 44 drug-free patients with major depression (35 women, 9 men) and 41 healthy controls (32 women, 9 men). We used the Hamilton Rating Scale for Depression to assess the severity of the patients’ depression. We assessed the controls’ mental health according to Diagnostic and Statistical Manual of Mental Disorders, 4th ed, criteria. To assess all participants’ stress levels, we used the Holmes and Rahe stress scale. We measured all participants’ serum BDNF and NGF levels via enzyme-linked immunosorbent assay. Results:The mean stress score was significantly higher in the patients than the controls (P=0.03). The patients had higher serum BDNF than the controls (P=0.001), but similar NGF levels. BDNF levels correlated negatively with symptom severity (r=−0.33, P=0.03) and duration (r=−0.2, P=0.06). NGF levels did not correlate with stress or with severity or duration of depressive episode. Conclusions:These findings suggest that an elevated serum BDNF level may contribute to the pathophysiology of major depressive disorder. The findings also indicate a possible role for BDNF in altering the clinical course of the condition.

Age-Dependent Changes in Plasma Amino Acids Contribute to Alterations in Glycoxidation Products

Summary Background: Glycative stress is involved in the pathogenesis of various degenerative disorders. This study sought to determine the effect of age-related changes in amino acids on serum levels of pentosidine and carboxymethyl-lysine (CML) in healthy individuals. Methods: The subjects were 78 healthy individuals categorized into three age groups. The ages of the groups were as follows: 26 young adults (20–30 y, 25.2±3.03), 26 middle-aged adults (35–50 y, 39.46±6.97) and 26 older adults (60 y or older, 69.80±10.01). Serum levels of pentosidine and CML were measured by ELISA and levels of plasma amino acids were determined using HPLC. Results: Serum levels of pentosidine and CML in the youngest group were higher than in the oldest group (p=0.026, 0.029, respectively). There was a positive correlation between the serum levels of pentosidine and CML and the levels of plasmaTyrosine (p=0.032, r=0.211 and p=0.037, r=0.224), Valine (p=0.037, r=0.224 and p=0.021, r=0.247) and Isoleucine (p=0.041, r=0.203 and p=0.021, r=0.247), respectively. Serum levels of pentosidine and CML may be modulated by the plasma levels of selected amino acids. Conclusions: Better understanding of the role of these selective amino acids might provide new perception of how glycation pathways may be altered and pave the way for new therapeutic principles.

Response to ‘Does l-Carnitine Supplementation Improve Sleep Quality in Children with Autism?’

First of all, it should be mentioned that in our study, autistic children were supplemented with carnosine and not carnitine and that the two terms should not be used interchangeably. Carnosine and carnitine are both dipeptides with different structures and functions, which are synthesized from different amino acids [2,3]. Carnitine is composed by lysine and methionine, which burns fat into energy and also transports toxic wastes out of the mitochondria. While carnosine is formed from alanine and histidine and functions as an antioxidant in the brain, nervous system and skeletal muscle, it inhibits protein carbonylation and glycoxidation and chelates metal ions. [4,5].

Changes of Insulin Resistance and Adipokines Following Supplementation with Glycyrrhiza Glabra L. Extract in Combination with a Low-Calorie Diet in Overweight and Obese Subjects: a Randomized Double Blind Clinical Trial

Purpose: Adipose tissue is a highly active endocrine organ which plays a key role in energy homeostasis. The aim of this study was to determine the effects of dried licorice extract along with a calorie restricted diet on body composition, insulin resistance and adipokines in overweight and obese subjects. Methods: Sixty-four overweight and obese volunteers (27 men, 37 women) were recruited into this double-blind, placebo-controlled, randomized, clinical trial. Participants were randomly allocated to the Licorice (n=32) or the placebo group (n=32), and each group received a low-calorie diet with either 1.5 g/day of Licorice extract or placebo for 8 weeks. Biochemical parameters, anthropometric indices, body composition and dietary intake were measured at baseline and at the end of the study. Results: A total of 58 subjects completed the trial. No side effects were observed following licorice supplementation. At the end of the study, waist circumference, fat mass, serum levels of vaspin, zinc-α2 glycoprotein, insulin and HOMA-IR were significantly decreased in the intervention group, but only the reduction in serum vaspin levels in the licorice group was significant when compared to the placebo group (p<0.01). Conclusion: Supplementation with dried licorice extract plus a low-calorie diet can increase vaspin levels in obese subjects. However, the anti-obesity effects of the intervention were not stronger than a low-calorie diet alone in the management of obesity.

Down-regulation of S100A1 protein in patients with metabolic syndrome and its association with zinc-α2-glycoprotein

Objectives It has been proposed that zinc-α2-glycoprotein and S100A1 are possibly linked to the development of lipogenesis and obesity. We aimed to measure serum levels of S100A1 and zinc-α2-glycoprotein in patients with metabolic syndrome and investigate any associations of these two novel peptides with each other or components of metabolic syndrome. Methods Forty-four patients with metabolic syndrome and the equivalent number of healthy controls participated in this study. The participants’ body mass index, waist circumference, systolic and diastolic blood pressure were measured. Serum levels of low- and high-density lipoprotein cholesterol, total cholesterol, triglyceride, fasting blood sugar, insulin, zinc-α2-glycoprotein and S100A1 protein were determined. Results Higher levels of anthropometric and lipid indices, metabolic factors and also SBP and DBP were observed in the metabolic syndrome group. Serum S100A1 levels were significantly lower in the metabolic syndrome group than the control group (P = 0.008). There was a strong positive correlation between serum zinc-α2-glycoprotein and S100A1 levels (r = 0.80, P < 0.0001). Serum levels of both S100A1 (P = 0.03) and zinc-α2-glycoprotein (P = 0.02) were potentially higher in subjects with hypertension than those with normal blood pressure, though these were found as part of multiple testing. Conclusion The results indicate that changes in the circulating level of S100A1 protein occur in metabolic syndrome patients. The strong correlation between serum zinc-α2-glycoprotein and S100A1 might suggest that production or release of these two proteins could be related mechanistically.